Literature DB >> 32476819

Patient reported outcome measures (PROMs) in sarcoidosis.

Rikke Flor Thunold1, Anders Løkke2, Adam Langballe Cohen1, Hilberg Ole3, Elisabeth Bendstrup2.   

Abstract

Patients with sarcoidosis present with a variety of symptoms which may impair many aspects of physical and mental well-being. Traditionally, clinicians have been concerned with physical health aspects of sarcoidosis, assessing disease activity and severity with radiological imaging, pulmonary function and blood tests. However, the most reported symptom of sarcoidosis patients, fatigue, has been shown not to correlate with the most commonly used parameters for monitoring disease activity. Studies have shown poor agreement between physicians and patients in assessing sarcoidosis symptoms. This underlines the importance of patient reported outcomes (PROs) in addition to traditional outcomes in order to provide a complete evaluation of the effects of interventions in clinical trials and everyday clinical assessment of sarcoidosis. We have undertaken a systematic review to identify and provide an overview of PRO concepts used in sarcoidosis assessment the past 20 years and to evaluate the tools used for measuring these concepts, called patient reported outcome measures (PROMs). Various PROMs have been used. By categorizing these PROMs according to outcome we identified the key PRO concepts for sarcoidosis to be Health Status and Quality of Life, Dyspnea, Fatigue, Depression, Anxiety and Stress and Miscellaneous. There is no perfect sarcoidosis-specific PROM to cover all concepts and future intervention studies should therefore contain multiple complementary questionnaires. Based on our findings we recommend the Fatigue Assessment Scale (FAS) for assessing fatigue. Dyspnea scores should be chosen based on their purpose; more research is needed to examine their validity in sarcoidosis. The Modified Medical Research Council Dyspnea Scale (MRC) can be used to screen for dyspnea and the Baseline Dyspnea Index (BDI) to detect changes in dyspnea. We recommend The World Health Organization Quality of Life assessment instrument (WHOQOL-100) for assessing quality of life, although a shorter questionnaire would be preferable. For assessing health status we recommend the Sarcoidosis Assessment Tool (SAT), and have great expectations for this new and promising assessment tool. Supplementary to the WASOG meeting of 2011's recommendation on assessing QoL, we recommend incorporating fatigue, dyspnea and HS assessment in clinical trials and everyday clinical assessment of sarcoidosis. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 2-17). Copyright:
© 2017.

Entities:  

Keywords:  PRO; PROM; clinical assessment; clinical trial; patient reported outcome; questionnaires; sarcoidosis

Year:  2017        PMID: 32476819      PMCID: PMC7170118          DOI: 10.36141/svdld.v34i1.5760

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN: 1124-0490            Impact factor:   0.670


  147 in total

1.  Small fibre neuropathy in sarcoidosis.

Authors:  E Hoitsma; M Marziniak; C G Faber; J P H Reulen; C Sommer; M De Baets; M Drent
Journal:  Lancet       Date:  2002-06-15       Impact factor: 79.321

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.

Authors:  G Lauria; S T Hsieh; O Johansson; W R Kennedy; J M Leger; S I Mellgren; M Nolano; I S J Merkies; M Polydefkis; A G Smith; C Sommer; J Valls-Solé
Journal:  Eur J Neurol       Date:  2010-07       Impact factor: 6.089

4.  An assessment of back pain and the prevalence of sacroiliitis in sarcoidosis.

Authors:  Nicola Erb; Michael J Cushley; Dimitrios G Kassimos; Ruth M Shave; George D Kitas
Journal:  Chest       Date:  2005-01       Impact factor: 9.410

5.  The internal consistency of PRO fatigue instruments in sarcoidosis: superiority of the PFI over the FAS.

Authors:  A Kalkanis; R M Yucel; M A Judson
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2013-03       Impact factor: 0.670

6.  Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis.

Authors:  A Baydur; M Alsalek; S G Louie; O P Sharma
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

7.  Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life.

Authors:  D Jastrzębski; D Ziora; M Lubecki; K Zieleźnik; M Maksymiak; J Hanzel; A Początek; A Kolczyńska; L Nguyen Thi; A Zebrowska; J Kozielski
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Authors:  Robert P Baughman; Marjolein Drent; Mani Kavuru; Marc A Judson; Ulrich Costabel; Roland du Bois; Carlo Albera; Martin Brutsche; Gerald Davis; James F Donohue; Joachim Müller-Quernheim; Rozsa Schlenker-Herceg; Susan Flavin; Kim Hung Lo; Barry Oemar; Elliot S Barnathan
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

9.  Therapeutic granulocyte and monocyte apheresis (GMA) for treatment refractory sarcoidosis: a pilot study of clinical effects and possible mechanisms of action.

Authors:  H H Olsen; V Muratov; K Cederlund; J Lundahl; A Eklund; J Grunewald
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

10.  The relationship between physical activity, functional performance and fatigue in sarcoidosis.

Authors:  Leorey N Saligan
Journal:  J Clin Nurs       Date:  2014-01-27       Impact factor: 3.036

View more
  3 in total

1.  Predictors of cough-specific and generic quality of life in sarcoidosis patients.

Authors:  Branislav S Gvozdenovic; Violeta V Mihailovic-Vucinic; Mira H Vukovic; Mihailo I Stjepanovic; Ivana Buha; Strahinja V Mihailovic; Nikola B Maric
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-06-30       Impact factor: 0.670

2.  A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis.

Authors:  Elliott D Crouser; Rachel M Smith; Daniel A Culver; Mark W Julian; Karen Martin; Joanne Baran; Christopher Diaz; Barbaros Selnur Erdal; Erinn M Hade
Journal:  Chest       Date:  2021-05-23       Impact factor: 10.262

3.  Scout - sarcoidosis outcomes taskforce. A systematic review of outcomes to inform the development of a core outcome set for pulmonary sarcoidosis.

Authors:  Nicola L Harman; Sarah L Gorst; Paula R Williamson; Elliot S Barnathan; Robert P Baughman; Marc A Judson; Heidi Junk; Nynke A Kampstra; Eugene J Sullivan; David E Victorson; Marc Walton; Tamara Al-Hakim; Hana Nabulsi; Noopur Singh; Jan C Grutters; Daniel A Culver
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2021-09-30       Impact factor: 0.670

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.